Effect of Metformin on Disease Progression in Patients With Cryptogenic Cirrhosis (NASH-related Cirrhosis) With Diabetes or Impaired Glucose Tolerance or Insulin Resistance

Institute of liver and Biliary Sciences0 个研究点目标入组 86 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1)Age 18 years and above
•2)Patients with cryptogenic cirrhosis {NASH (Nash Alcoholic Steatohepatitis)-related cirrhosis}
•3)Presence of diabetes mellitus or insulin resistance

•1)Patients with heart failure
•2)Patients with acute kidney injury at the time of enrollment
•3)Patients with CKD (Chronic Kidney Disease) or with S. Creatinine > 1 mg/dL
•4)Patient with active upper GI bleeding- not settled
•5)Patient with SIRS/sepsis/shock
•6)Patient in ICU (Intensive Care Unit)
•7)Pregnancy
•8)Patients with hepatocellular carcinoma
•9)Patients who are not willing to participate in the study
•10)Patients with any form of decompensation at the time of enrollment in the study
•11)Patient with large esophageal varices/ patients who are on beta blocker other than those patients with HVPG (Hepatic Venous Pressure Gradient) non responder to betablocker
•12)Patient who has already been receiving Metformin prior to enrollment in the study

发起方